Progressive dementia with neuroserpin inclusion bodies

Summary

Progressive dementia with neuroserpin inclusion bodies (MONDO:0035161) is a disease. A subtype of dementia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	progressive dementia with neuroserpin inclusion bodies
Mondo ID	MONDO:0035161
Orphanet	530303
ICD-10-CM	G40.3
UMLS	C5680143
MedGen	1842194
GARD	0022208
Is cancer (heuristic)	no

Also known as: late-onset familial encephalopathy with neuroserpin inclusion bodies

Disease family

This is a subtype of dementia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › cognitive disorder › dementia › progressive dementia with neuroserpin inclusion bodies

Related subtypes (8): vascular dementia, Alzheimer disease, Lewy body dementia, hereditary dementia, dementia pugilistica, parkinsonism with dementia of Guadeloupe, AIDS dementia complex, childhood-onset dementia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.